Študija 316 je bila randomizirano, dvojno slepo preskušanje uporabe peroralne suspenzije posakonazola (200 mg trikrat na dan) v primerjavi s flukonazolom v kapsulah (400 mg enkrat na dan) pri prejemnikih alogenskega transplantata z boleznijo presadka proti gostitelju (GVHD).
Study 316 was a randomised, double-blind trial of posaconazole oral suspension (200 mg three times a day) versus fluconazole capsules (400 mg once daily) in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD).